Sorbentogel

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT SORBENTOGEL (SORBENTOGEL)

Composition:

Active substance: methylsilicic acid hydrogel;

1 g of the preparation contains 0.7 g of methylsilicic acid hydrogel;

Excipient: purified water.

Pharmaceutical form. Oral gel.

Main physicochemical properties: homogeneous gel-like mass, white to almost white in color, odorless.

Pharmacotherapeutic group. Agents affecting the digestive system and metabolism. Antidiarrheal agents, drugs used for the treatment of infectious and inflammatory intestinal diseases. Enterosorbents. Other enterosorbents. ATC code A07BC.

Pharmacological Properties

Pharmacodynamics

Sorbentogel is an inert silicon-organic compound. When administered, it exhibits sorption activity. The medicinal product effectively adsorbs medium-molecular toxic substances of exogenous and endogenous origin, products of incomplete metabolism, incorporated radionuclides, and naturally eliminates them from the body.

The drug eliminates manifestations of intoxication, improves detoxification functions of the intestine, liver, and kidneys, and normalizes blood and urine parameters.

By coating the mucous membranes of the stomach and intestines, the drug protects them from erosive processes and promotes enhancement of local immunity.

Pharmacokinetics

Sorbentogel is not absorbed from the gastrointestinal tract and undergoes neither metabolic nor chemical transformations.

Clinical characteristics.

Indications.

As part of complex detoxification therapy in chronic renal failure; in toxic hepatitis, viral hepatitis A and B, liver cirrhosis, and cholestasis of various etiologies; in enterocolitis, colitis, diarrhea, gastritis with reduced acidity, and in alcohol and drug intoxication; in allergic and skin diseases (diathesis, neurodermatitis); in burn intoxication; in purulent-septic and inflammatory processes accompanied by intoxication; in first-trimester pregnancy toxemias; as part of complex treatment of intestinal dysbiosis.

Contraindications.

Acute intestinal obstruction.

Interaction with other medicinal products and other forms of interaction.

The drug may reduce the effect of other medicinal products taken concurrently.

Provided the recommended administration method is followed (Sorbentogel and medicinal products are taken at an interval of 1.5–2 hours), the drug can be used in combination therapy with other medicinal and prophylactic agents, including prebiotics and probiotics (bifidobacteria, lactobacilli), phytopreparations, adaptogens, and immunomodulators. Simultaneous use with drugs belonging to the bile acid sequestrant class, such as cholestyramine, is not recommended due to increased risk of constipation development.

Sorbentogel should not be used concomitantly with silver-containing products.

Special precautions for use.

Use during pregnancy or breastfeeding.

The medicinal product can be used during pregnancy or breastfeeding. Its use should be limited in pregnant women who are prone to constipation.

Ability to affect reaction rate when driving or operating machinery.

No effect.

Dosage and Administration.

Take orally 3 times daily, 1.5–2 hours before or 2 hours after meals or taking other medications, with sufficient amount of water.

For adults and children aged 14 years and older: single dose is 15 g (tablespoon), daily dose is 45 g.

For children from birth to 5 years: single dose is 5 g (teaspoon), daily dose is 15 g; for children aged 5 to 14 years: single dose is 10 g (dessert spoon), daily dose is 30 g.

Treatment duration: 7 to 14 days.

In severe cases, during the first three days double single dose may be used. In chronic conditions (e.g., chronic renal insufficiency), the drug may be administered for a longer period (up to 1 month).

Children.

The medicinal product can be used in children from birth. For children under 2 years of age, the single dose may be mixed with a small amount of water prior to administration.

Overdose.

Cases of overdose have not been reported.

In case of overdose, adverse effects may be intensified.

Adverse reactions.

Dyspeptic symptoms may occur during administration of the medicinal product. Constipation may develop during the first days of treatment. To prevent constipation, patients prone to this condition should be administered an enema at night or laxatives (lactulose, sodium picosulfate) during the first two days of treatment.

Shelf life. 2 years from the date of manufacture of the product in "in bulk" packaging.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °C.

Do not allow freezing. After freezing, the product loses its properties.

After opening the packaging, store under the same conditions in tightly closed containers.

Keep out of reach of children.

Packaging. 135 g, 270 g, or 405 g in a container in a box.

Dispensing category. Over-the-counter.

Manufacturer. Limited Liability Company "Pharmaceutical Company "Vertex".

Manufacturer's address and location of business activity.

33, Astronomichna Street, lit. "V-1", Kharkiv, Kharkiv region, 61085, Ukraine.